RxDoctor Payments Data

Naomi Flock, MD

Adult Medicine · Port Orange, FLNPI 1164840351

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations.

$2,768in general payments, 2019–2025

Across 146 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$493
  • Pfizer$479
  • GSK$422
  • AbbVie$229
  • Phathom Pharmaceuticals, Inc.$183
  • Renalytix AI, Inc.$136
  • plus $827 from 20 others

What the payments were for

  • Food & beverage$2,768100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,768 in reported general payments places this provider in the 85th percentile of 195 adult medicine providers in Florida.

See all adult medicine providers in Florida

Medicare billing

Part B allowed, 2024
$19,050
Medicare patients
71
Services billed
197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$33,029
OzempicSemaglutide28$27,753
RybelsusSemaglutide15$23,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$18,264
Celecoxib17$2,317
Estradiol36$2,241
SynthroidLevothyroxine Sodium17$2,002
Atorvastatin Calcium180$1,682
Gabapentin41$1,116
Levothyroxine Sodium123$1,078
ValacyclovirValacyclovir Hcl11$934
Albuterol Sulfate HfaAlbuterol Sulfate22$787
Omeprazole56$752
Amlodipine Besylate124$735
Fluticasone Propionate37$715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$493$51,65643 claims
PfizerEliquis$479$33,02938 claims
GSKTrelegy Ellipta$422$18,26427 claims
AbbVieSynthroid$229$2,00217 claims
Lilly USA, LLCOlanzapine$41$59714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 195 adult medicine providers in Florida.

Other adult medicine in Port Orange

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →